4 completed, 3 terminated, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 4 Phase 2, 2 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Hookipa Biotech GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer HB-202/HB-201 alternating 2-vector therapy, Placebo, Pembrolizumab - Oropharyngeal Squamous Cell Carcinoma Recurrent | Phase 2 / Phase 3 | Withdrawn | Hookipa Biotech GmbH | 2024-12-01 | 2025-06-22 | |
| Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo - Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Terminated | Hookipa Biotech GmbH | 30 | 2024-07-01 | 2025-11-18 |
| Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma Pembrolizumab, Nivolumab - Oropharyngeal Squamous Cell Carcinoma | Completed | Hookipa Biotech GmbH | 662 | 2024-06-05 | 2025-09-09 | |
| A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) HB-200 - HPV16+ Squamous Cell Carcinoma | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 7 | 2024-04-15 | 2026-01-20 |
| HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer HB-302/HB-301 Alternating 2-Vector Therapy - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Hookipa Biotech GmbH | 12 | 2023-05-23 | 2024-06-12 |
| A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer HB-201 IV - HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer | Early Phase 1 | Terminated | AstraZeneca | 10 | 2021-07-21 | 2026-09-14 |
| A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab. - HPV-Related Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Hookipa Biotech GmbH | 198 | 2019-12-11 | 2025-09-15 |
| A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients HB-101 vaccine, placebo - Cytomegalovirus (CMV) Infection, Kidney Transplantation | Phase 2 | Completed | Hookipa Biotech GmbH | 83 | 2018-12-12 | 2023-10-26 |
| Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV Low dose HB-101, Medium dose HB-101, High dose HB-101 - Cytomegalovirus Infection | Phase 1 | Completed | Hookipa Biotech GmbH | 54 | 2016-06-01 | 2018-04-03 |
Head and Neck Neoplasms (3) · Neoplasms, Squamous Cell (3) · Squamous Cell Carcinoma of Head and Neck (3) · Cytomegalovirus Infections (2) · Oropharyngeal Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Uterine Cervical Neoplasms (1)
pembrolizumab (3) · Nivolumab (1)
United States (7) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Netherlands (1) · Norway (1) · Spain (1) · United Kingdom (1)
Geert Leroux-Roels, MD PhD Prof (1) · Winston Wong, MD (1)
2017 (1), 2019 (1)